307 related articles for article (PubMed ID: 28187774)
1. Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.
Kassai S; Pintér JN; Rácz J; Böröndi B; Tóth-Karikó T; Kerekes K; Gyarmathy VA
Harm Reduct J; 2017 Feb; 14(1):9. PubMed ID: 28187774
[TBL] [Abstract][Full Text] [Related]
2. Do police arrestees substitute legal highs for other drugs?
Wilkins C; Parker K; Prasad J; Jawalkar S
Int J Drug Policy; 2016 May; 31():74-9. PubMed ID: 26948501
[TBL] [Abstract][Full Text] [Related]
3. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis.
Mensen VT; Vreeker A; Nordgren J; Atkinson A; de la Torre R; Farré M; Ramaekers JG; Brunt TM
Psychopharmacology (Berl); 2019 Sep; 236(9):2677-2685. PubMed ID: 30968175
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.
Tait RJ; Caldicott D; Mountain D; Hill SL; Lenton S
Clin Toxicol (Phila); 2016; 54(1):1-13. PubMed ID: 26567470
[TBL] [Abstract][Full Text] [Related]
5. [Assessing identity formation of synthetic cannabinoid products' users - an interpretative phenomenological analysis].
Pintér JN; Kassai S; Rácz J
Psychiatr Hung; 2016; 31(4):313-326. PubMed ID: 28032580
[TBL] [Abstract][Full Text] [Related]
6. Uses, Effects and Toxicity of Synthetic Cannabinoids from the Perspective of People with Lived Experiences.
Assi S; Marshall D; Bersani FS; Corazza O
J Psychoactive Drugs; 2020; 52(3):237-247. PubMed ID: 32027228
[TBL] [Abstract][Full Text] [Related]
7. [Motivations for cannabis cessation, coping and adaptation strategies, and perceived benefits: impact on cannabis use relapse and abstinence].
Chauchard E; Septfons A; Chabrol H
Encephale; 2013 Dec; 39(6):385-92. PubMed ID: 23928064
[TBL] [Abstract][Full Text] [Related]
8. A survey of synthetic cannabinoid consumption by current cannabis users.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Subst Abus; 2014; 35(2):184-9. PubMed ID: 24821356
[TBL] [Abstract][Full Text] [Related]
9. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.
Cooper ZD
Curr Psychiatry Rep; 2016 May; 18(5):52. PubMed ID: 27074934
[TBL] [Abstract][Full Text] [Related]
10. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample.
Winstock A; Lynskey M; Borschmann R; Waldron J
J Psychopharmacol; 2015 Jun; 29(6):698-703. PubMed ID: 25759401
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
[TBL] [Abstract][Full Text] [Related]
12. A preliminary evaluation of synthetic cannabinoid use among adolescent cannabis users: Characteristics and treatment outcomes.
Blevins CE; Banes KE; Stephens RS; Walker DD; Roffman RA
Addict Behav; 2016 Dec; 63():114-9. PubMed ID: 27454353
[TBL] [Abstract][Full Text] [Related]
13. The Synthetic Cannabinoids Phenomenon.
Karila L; Benyamina A; Blecha L; Cottencin O; Billieux J
Curr Pharm Des; 2016; 22(42):6420-6425. PubMed ID: 27655416
[TBL] [Abstract][Full Text] [Related]
14. Synthetic cannabinoids: the dangers of spicing it up.
Salani DA; Zdanowicz MM
J Psychosoc Nurs Ment Health Serv; 2015 May; 53(5):36-43. PubMed ID: 25974923
[TBL] [Abstract][Full Text] [Related]
15. Synthetic cannabinoid withdrawal: a new demand on detoxification services.
Macfarlane V; Christie G
Drug Alcohol Rev; 2015 Mar; 34(2):147-53. PubMed ID: 25588420
[TBL] [Abstract][Full Text] [Related]
16. [Synthetic cannabinoids: spread, addiction biology & current perspective of personal health hazard].
Bonnet U; Mahler H
Fortschr Neurol Psychiatr; 2015 Apr; 83(4):221-31. PubMed ID: 25893495
[TBL] [Abstract][Full Text] [Related]
17. Differences between users' and addiction medicine experts' harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization/restriction debates.
Bonnet U; Specka M; Kanti AK; Scherbaum N
Front Psychiatry; 2022; 13():1041762. PubMed ID: 36465301
[TBL] [Abstract][Full Text] [Related]
18. A review on the abuse of three NPS (synthetic cannabinoids, kratom, poppers) among youths in Asia.
Bae K; Kwon NJ; Han E
Forensic Sci Int; 2018 Nov; 292():45-49. PubMed ID: 30273913
[TBL] [Abstract][Full Text] [Related]
19. 'Spice' Use Motivations, Experiences, and Repercussions among Veterans of the United States Armed Forces.
Stogner J; Baldwin JM; Wiercioch A
Subst Use Misuse; 2024; 59(8):1182-1189. PubMed ID: 38548662
[TBL] [Abstract][Full Text] [Related]
20. Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016.
Springer YP; Gerona R; Scheunemann E; Shafer SL; Lin T; Banister SD; Cooper MP; Castrodale LJ; Levy M; Butler JC; McLaughlin JB
MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(40):1108-1111. PubMed ID: 27736839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
